The antiandrogen withdrawal syndrome in relapsed prostate cancer. Academic Article uri icon

Overview

abstract

  • Evolving data suggest that palliation of relapsed prostate cancer can be achieved by the selective discontinuation of agents that act via steroid hormone receptors. Clinical benefit has been observed following the withdrawal of flutamide (Eulexin, Schering-Plough International), bicalutamide (Casodex, Zeneca Ltd), oestrogens, progestational agents and retinoids. For patients with progression of disease while receiving these drugs, a period of observation after withdrawal should be considered before further therapy is initiated.

publication date

  • January 1, 1997

Research

keywords

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Palliative Care
  • Prostatic Neoplasms

Identity

Scopus Document Identifier

  • 0031048446

Digital Object Identifier (DOI)

  • 10.1159/000474540

PubMed ID

  • 9074903

Additional Document Info

volume

  • 31 Suppl 2